CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1–positive regulator for tumor immune evasion is a research paper published in Journal of Clinical Investigation (2023). On theSindex it has a DataRank of 0. It has been cited 35 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH
Grant: R01DK126908,R01DK120330,R01CA257520,CA232347
National Natural Science Foundation of China
Grant: 82073768
Shandong Province Natural Science Foundation
Grant: ZR2019MH110
Dalian High-level Talent Innovation Support Program
Grant: 2019RD03
NIDDK NIH HHS
Grant: R01 DK126908
NCI NIH HHS
Grant: R01 CA232347
NCI NIH HHS
Grant: R01 CA257520
NIDDK NIH HHS
Grant: R01 DK120330
National Institutes of Health
Grant: 1R01CA257520-01
A deubiquitination module controls Treg adaptation to tumor microenvironment
National Institutes of Health
Grant: 5R01CA232347-04
Targeting a Treg deubiquitinase in antitumor immune therapy
National Institutes of Health
Grant: 7R01DK120330-06
Novel role of hepatic SEL1L-HRD1 ERAD in bile acid metabolism
National Institutes of Health
Grant: 5R01DK126908-04
Regulation of Rhythmic m6A RNA Modification by ER‐associated Degradation
Fields of Study
MeSH Terms
Keywords